Yet another potential anticancer mechanism of fingolimod is inhibition or degradation of SK1, which is upregulated in multiple cancers, including CNS (brain), gastrointestinal (colon, stomach, rectum, small intestine), genitourinary (ovary and uterus), pulmonary and breast (121). This evidence concerns the gene SPHK1 and cancer.